Dimethyl Fumarat – a New Player in Oral Treatment Options for Relapsing Forms of Multiple Sclerosis
One of the latest oral treatment options for relapsing forms of multiple sclerosis is dimethyl fumarat, approved by FDA on February 2013 and by EMA on January 2014 (1, 2).
The mechanism of action of dimethyl fumarat (DMF) in multiple sclerosis is not completely understood. DMF and its active metabolite, monomethyl fumarate (MMF) has been shown to activate the nuclear factor (erythroid-derived)-like 2 (NrF2) pathway in vitro and in vivo in animals and humans. The NrF2 pathway is involved in the cellular response to oxidative stress and regulates “antioxidant” genes involved in protecting cells from damage (2, 3).